Análisis de la acción ABVC Biopharma Inc (ABVC)

Análisis de IA of ABVC Biopharma Inc (ABVC)

Mantener

ABVC Biopharma Inc is currently trading at $0.98, which is significantly lower than its 52-week high of $3.06, indicating a potential undervaluation. However, the stock has a low RSI of 36.75, suggesting it is nearing oversold territory, but it has also experienced a substantial year-to-date decline of 55.25%. The company has reported no revenue for several quarters, and its forward P/E ratio is 0, indicating uncertainty about future earnings. The main risk is the negative net income trend, with losses reaching -$3.56 million in Q4 2025. Therefore, while there are signs of potential recovery, the lack of revenue and ongoing losses suggest a cautious approach is warranted.

Métricas de valoración

El PER previsto actual de ABVC Biopharma Inc (ABVC) es 0.00, frente a su media de 5 años de -1.92.

PER previsto

Valor razonable

Media 5A P/E

-1.92

P/E actual

0.00

Sobrevalorada

1.06

Infravalorada

-4.90

EV/EBITDA previsto

Muy infravalorado

Media 5A EV/EBITDA

0.00

EV/EBITDA actual

0.00

Sobrevalorada

0.00

Infravalorada

0.00

Precio/ventas previsto

Valor razonable

Media 5A P/S

116.68

P/S actual

0.00

Sobrevalorada

431.38

Infravalorada

-198.03

Escenarios de precio de Alphio AI para ABVC

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%ABVC

$3.35

Precio del escenario

B

Base

Base · 50%ABVC

$3.17

Precio del escenario

B

Bajista

Bajista · 25%ABVC

$2.76

Precio del escenario

Preguntas frecuentes sobre ABVC, respondidas por Alphio AI

ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ABVC Biopharma Inc is currently trading at $0.98, which is significantly lower than its 52-week high of $3.06, indicating a potential undervaluation. However, the stock has a low RSI of 36.75, suggesting it is nearing oversold territory, but it has also experienced a substantial year-to-date decline of 55.25%. The company has reported no revenue for several quarters, and its forward P/E ratio is 0, indicating uncertainty about future earnings. The main risk is the negative net income trend, with losses reaching -$3.56 million in Q4 2025. Therefore, while there are signs of potential recovery, the lack of revenue and ongoing losses suggest a cautious approach is warranted.